AGC Biologics has manufacturing sites in Japan, the US, and Europe, from which it provides a wide variety of high value-added services that range from process development to upscaling, clinical trials, and commercial drug manufacturing. The company has been selected as a manufacturing partner for this new therapeutic drug candidate for COVID-19 in recognition of its decades-long successful track record as a CDMO as well as the company's high-level quality and service advantages that are globally consistent.
The AGC Group is committed to helping prevent the spread of COVID-19 and end this pandemic by playing its role in the manufacture of COVID-19 vaccines and drugs for pharmaceutical companies.
Molecular Partners AG is a clinical-stage biotech developing a new class of custom-built proteins known as DARPin® therapeutics, designed to address challenges current modalities cannot. The company has compounds in various stages of clinical and preclinical development with a focus on oncology. The company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics across multiple therapeutic areas. Visit the URL below for more details.
*1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted or acts on behalf of another company to handle product manufacturing as well as the development of manufacturing methods.
*2 DARPin® anti-COVID-19 program: a unique tri-specific approach binding to the spike proteins on the surface of COVID-19. Based upon preliminary potency data, a subcutaneous administration of MP0420 could function as both a therapeutic for existing viral infection and as a potential preventive therapy.